Results 131 to 140 of about 77,862 (256)

Bioassays in Allergy: Technical Characteristics, Limitations, and Pathways to Clinical Implementation—An EAACI Position Paper

Clinical and Translational Allergy, Volume 16, Issue 10, October 2026.
ABSTRACT Bioassays offer functional readouts of immune responses through specific biomarkers, providing mechanistic insight beyond conventional serology. By capturing cellular activation, tissue‐level changes, and molecular signaling, they hold promise for refining allergy diagnosis, risk stratification, and treatment monitoring, contributing to ...
Cagatay Karaaslan, Oscar Palomares, Busra Kilic, Cristobalina Mayorga, Hans Jürgen Hoffmann, Bernadette Eberlein, Edward Knol, Ruben Fernandez‐Santamaria, Joana Vitte, Elena Izquierdo, Cristina Gomez‐Casado, Marina Perez‐Gordo, Araceli Diaz Perales, Maria M. Escribese   +13 more
wiley   +1 more source

Adverse Reactions Identified after Approval of Novel Medicines: Analysis of 339 New Molecular Entities and Therapeutic Biologics

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1120-1128, October 2026.
Postmarketing safety surveillance data identify safety issues not identified in preapproval clinical trials. We describe the frequency of new safety issues overall and by labeling section and the relationship of the most commonly added safety issues with the cumulative number of prescriptions dispensed via retail pharmacies.
Ellen Pinnow, Brendan Day, Esther H. Zhou, Corinne Woods, Nana Dwumfour, Jenni Y. Lee, Ilynn Bulatao, Sanae Cherkaoui, Manish Kalaria, Sonja Brajovic, Nabila Sadiq, Farideh Sistani, Maggie Lee, Grace Chai, Gerald Dal Pan   +14 more
wiley   +1 more source

Graft‐Versus‐Tumour Effect Following Allogeneic Haematopoietic Stem Cell Transplantation in a Paediatric Patient With Mogamulizumab‐Treated Primary Cutaneous Peripheral T‐Cell Lymphoma

eJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Introduction Primary cutaneous peripheral T‐cell lymphoma, not otherwise specified (pcPTCL‐NOS), is exceptionally rare in children, and evidence guiding diagnosis and treatment is limited. Case Presentation A 10‐year‐old boy with pcPTCL‐NOS refractory to chemotherapy received mogamulizumab prior to allogeneic haematopoietic stem cell ...
Maria Ebbesen Sørum, Tania Masmas, Hilde Uhlving, Lene D. Sjö, Signe Modvig, Hanne V. Marquart, Lone Skov, Lisa Hjalgrim, Marianne Ifversen, Peter Pontoppidan   +9 more
wiley   +1 more source

Eosinophilic cationic protein and D-Dimer are potential biomarkers to predict response to antihistamines but not to omalizumab in chronic spontaneous urticaria

Libyan Journal of Medicine
Introduction: Biomarkers that could reliably anticipate the effectiveness of antihistamines and omalizumab in treating chronic spontaneous urticaria (CSU) have not been conclusively identified.
O. S. Atik, F. M. Tepetam, Ş. Özden, E. Kocatürk   +3 more
semanticscholar   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

MedComm, Volume 7, Issue 10, October 2026.
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley   +1 more source

Differential Effects of Dupilumab in a Patient With Localized Heat Urticaria, Delayed Solar Urticaria, and Symptomatic Dermographism

The Journal of Dermatology, Volume 53, Issue 10, Page 1525-1528, October 2026.
ABSTRACT Physical urticaria is a subtype of chronic inducible urticaria characterized by wheals and/or angioedema triggered by physical stimuli. We report a refractory case of combined localized heat urticaria, delayed solar urticaria, and symptomatic dermographism in a 16‐year‐old girl.
Shuta Yoshitani, Shinichi Moriwaki, Atsushi Fukunaga   +2 more
wiley   +1 more source

Non-Skin-Related Symptoms are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results from CURE.

Journal of Allergy and Clinical Immunology: In Practice
BACKGROUND Chronic spontaneous urticaria (CSU) can present with non-skin-related symptoms (NSRS), including recurrent unexplained fever, joint/bone/muscle pain (JBMP), and malaise, which also occur in other conditions that manifest with wheals (e.g ...
P. Pyatilova, Yana Hackler, F. Aulenbacher, R. Asero, A. Bauer, M. Bizjak, C. Day, Joachim Dissemond, A. Du-Thanh, D. Fomina, A. Giménez-Arnau, C. Grattan, S. Gregoriou, T. Hawro, A. Kasperska-Zając, M. Khoshkhui, E. Kocatürk, E. Kovalkova, K. Kulthanan, E. Kuznetsova, M. Makris, Olga A. Mukhina, D. Pesqué, J. Peter, P. Salameh, F. Siebenhaar, A. Sikora, P. Staubach, P. Tuchinda, Mateusz Zamłyński, K. Weller, Marcus Maurer, P. Kolkhir   +32 more
semanticscholar   +1 more source

Emerging Paediatric Uses of Dupilumab Beyond Approvals

Clinical &Experimental Allergy, Volume 56, Issue 10, Page 1162-1176, October 2026.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia   +11 more
wiley   +1 more source

Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria

Archives of Dermatological Research
While several studies have examined the role of T cells and related cytokines in the development of chronic spontaneous urticaria (CSU), there is a limited amount of research focusing on the changes in cytokine levels during omalizumab treatment.
Selcen Hoşgören-Tekin, İ. P. Eyüboğlu, M. Akkiprik, A. Giménez-Arnau, A. Salman   +4 more
semanticscholar   +1 more source

Remibrutinib as a Therapeutic Option for Solar Urticaria

Photodermatology, Photoimmunology &Photomedicine, Volume 42, Issue 6, November 2026.
Joshua Mijares, Manoj Bhagwat, Johanna Gonzalez, Vignesh Ramachandran   +3 more
wiley   +1 more source